Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Avadel Pharmaceuticals PLC
Research & Development
Avadel Pharmaceuticals PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Research & Development
-$39.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-4%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Research & Development
-$95.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Research & Development
-$782.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-19%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Research & Development
-$38.7m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-158%
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Research & Development
-€47.1m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-7%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Research & Development
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Research & Development?
Research & Development
-39.9m
USD
Based on the financial report for Sep 30, 2025, Avadel Pharmaceuticals PLC's Research & Development amounts to -39.9m USD.
What is Avadel Pharmaceuticals PLC's Research & Development growth rate?
Research & Development CAGR 10Y
-4%
Over the last year, the Research & Development growth was -200%. The average annual Research & Development growth rates for Avadel Pharmaceuticals PLC have been -34% over the past three years , -12% over the past five years , and -4% over the past ten years .
